Cardiol Therapeutics

The model outputs a Neutral rating for Cardiol Therapeutics, scoring 50/100 at conviction 1 of 5. Four pillars feed the composite in fixed weights (35/25/25/15 for fundamentals, regulatory, market, and editorial), and no clause of the score is hidden from the reader. Regulatory carries this profile, printing 69 and setting the ceiling on the composite. The editorial pillar sits at 30, and is the main drag on the composite.

Pillar-level, the record reads as reported revenue growth of 0.0 percent year over year, an operating margin of 0.0 percent, a market cap near 116 million, a filing cadence of 3 regulator events in the trailing 90 days, a jurisdictional posture reading of 80. Each of those data points tethers the Neutral conclusion to observable evidence. The scoring pipeline pulls only from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage, and each pillar exposes its own inputs. This lets Cardiol Therapeutics be lined up against the global cannabis coverage universe on identical inputs, with refresh cadence tied directly to primary-source ingest.

Filing cadence and jurisdictional posture remain the primary drivers, with regulatory contributing 69. A sustained lift in filing frequency across the trailing 90 days combined with zero enforcement events would tighten the Neutral conclusion.